About This Reference Desk

What AgeDefy Peptide is

AgeDefy Peptide is an independent editorial reference desk covering the published research on two molecules studied for longevity and cellular health: NAD+ (nicotinamide adenine dinucleotide) and MOTS-c (the mitochondrial-derived peptide encoded in the 12S rRNA gene). The site exists to make a scattered, unevenly reported, and frequently overclaimed literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which species, and how far that evidence reaches.

The organizing idea is cellular aging from two angles: the coenzyme that powers and regulates the cell (NAD+) and the peptide that the mitochondrion itself produces as a stress and aging signal (MOTS-c). Both have been investigated in the context of age-related metabolic decline and longevity biology, and both illustrate a central challenge in the field: translating compelling preclinical and mechanistic data into validated human outcomes. Each compound has its own page; a comparison page lines them up side by side; and a single shared references list aggregates every source.

How it is compiled

Three principles govern what appears on this site.

First, everything is anchored to the peer-reviewed literature. Every research claim is tied to a numbered citation — PubMed-indexed journal articles and reviews, with DOIs or PubMed links — collected on the references page. Where a finding comes from a review rather than a primary study, the review is cited as such.

Second, the evidence is reported at its true strength. Doses are described in the species and route in which they were studied — for example, "studied at 0.5-15 mg/kg/day in mice" — never scaled to humans or offered as a recommendation. Where evidence is preclinical, observational, or rests on a proxy measure (such as blood NAD+ elevation rather than a hard clinical endpoint), the page says so plainly. That candor about limits is the purpose of the desk, not an afterthought to it.

Third, the two pages are cross-referenced. Because the same themes — mitochondrial function, AMPK signaling, cellular energy, age-related metabolic decline — recur across both compounds, the pages link to one another and to the comparison page so a reader can follow a mechanism through the full landscape.

What it is not

AgeDefy Peptide is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any research compound, dietary supplement, or IV therapy, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person, and it never frames an animal-study dose as something a human should take.

The molecules discussed here occupy different regulatory niches: NAD+ precursors are widely sold as supplements and administered as compounded IV therapy, while MOTS-c is a research chemical sold for laboratory use only. Neither is an approved medicine for age-related conditions; MOTS-c is explicitly prohibited in sport. Readers interested in any condition described in the underlying research should consult a licensed clinician in their own jurisdiction, working with regulated, evidence-based options. The value this desk offers is a calm, accurate map of the published literature — nothing more, and nothing it pretends to be.